# MAGEA4

## Overview
MAGEA4 is a gene that encodes the protein MAGE family member A4, which is part of the melanoma-associated antigen (MAGE) protein family. This family is characterized by its involvement in various cellular processes, particularly in the context of cancer biology. MAGEA4 is notable for its role in stabilizing the RING E3 ubiquitin ligase RAD18, thereby influencing DNA damage tolerance pathways and genomic stability (Griffith-Jones2023Structural). The protein MAGEA4 contains a conserved C-terminal MAGE Homology Domain (MHD), which is essential for its interactions with other proteins, such as RAD18, and contributes to its function in DNA repair processes (Hagiwara2016Consequences). MAGEA4 is predominantly expressed in the testes under normal physiological conditions but is aberrantly expressed in various cancers, where it is associated with tumor progression and poor prognosis (Verma2024Melanoma; Hagiwara2016Consequences). Due to its specific expression pattern and functional implications in cancer, MAGEA4 is considered a potential target for cancer immunotherapy and a biomarker for treatment outcomes (Li2021Pathogenicity; Freiberger2022Combinational).

## Structure
MAGEA4, a member of the MAGE protein family, exhibits a complex molecular structure characterized by several distinct features. The primary structure of MAGEA4 includes a conserved C-terminal MAGE Homology Domain (MHD), which is crucial for its function and interactions (Hagiwara2016Consequences). This domain contains winged-helix (WH) subdomains, specifically WH-A and WH-B, which are important for stabilizing interactions with other proteins, such as RAD18 (Griffith-Jones2023Structural; Gao2016A).

The secondary structure of MAGEA4 includes both ordered and disordered regions. The N-terminal region is largely disordered, while the C-terminal MHD forms a structured hydrophobic core (Hagiwara2016Consequences). The tertiary structure of MAGEA4 is predominantly globular, with some extended states, as indicated by its broad charge state distribution in mass spectrometry analyses (Hagiwara2016Consequences).

In terms of quaternary structure, MAGEA4 can form dimers, although the functional implications of this dimerization are not fully understood (Hagiwara2016Consequences). MAGEA4 also interacts with RAD18, forming a complex that influences DNA damage tolerance pathways (Griffith-Jones2023Structural). These structural characteristics are significant for MAGEA4's role in cancer biology and its potential as a therapeutic target.

## Function
MAGEA4, a member of the MAGE family, plays a significant role in cellular processes by interacting with RAD18, a RING E3 ubiquitin ligase. In healthy human cells, particularly in the testes, MAGEA4 stabilizes RAD18 by preventing its autoubiquitination, which would otherwise lead to its degradation. This stabilization is crucial for the regulation of DNA damage tolerance pathways, essential for maintaining genomic stability during cell division and replication (Griffith-Jones2023Structural). MAGEA4 binds to the RAD6-binding domain (R6BD) of RAD18, forming a complex that includes RAD6, which is involved in DNA repair processes (Griffith-Jones2023Structural).

The interaction between MAGEA4 and RAD18 is characterized by hydrophobic interactions and a salt bridge, which helps maintain RAD18's stability and function in DNA repair, particularly in the monoubiquitination of PCNA, a process important for DNA repair (Griffith-Jones2023Structural). This interaction is specific and crucial for the long-term maintenance of spermatogenesis, highlighting MAGEA4's role in reproductive biology (Griffith-Jones2023Structural).

## Clinical Significance
MAGEA4 is implicated in various cancers due to its altered expression and mutations. It is frequently overexpressed in several tumor types, including melanoma, lung, ovarian, breast, and bladder cancers, where it is associated with tumor progression and poor prognosis (Li2021Pathogenicity; Verma2024Melanoma; Hagiwara2016Consequences). In bladder cancer, MAGEA4 expression correlates with higher-grade tumors and an invasive phenotype, significantly impacting survival rates (Verma2024Melanoma).

Mutations in MAGEA4, such as E221K and E242K, can affect the protein's thermal stability and potentially alter its function in cancer cells (Hagiwara2016Consequences). These mutations are observed in melanoma, suggesting a role in tumorigenesis (Caballero2010Frequent). MAGEA4's interaction with proteins like p53 and gankyrin can inhibit apoptosis and promote tumor growth, contributing to its oncogenic potential (FujiwaraKuroda2018Prognostic; Hagiwara2016Consequences).

In mucosal melanoma, MAGEA4 expression is linked to better responses to immunotherapy, indicating its potential as a predictive biomarker for treatment outcomes (Freiberger2022Combinational). The gene's expression and mutations make it a target for cancer immunotherapy, highlighting its clinical significance in oncology (Li2021Pathogenicity; Tsang2020Differential).

## Interactions
MAGEA4 interacts with RAD18, a RING E3 ubiquitin ligase, playing a crucial role in the trans-lesion synthesis (TLS) pathway. MAGEA4 stabilizes RAD18 by protecting it from ubiquitin-coupled proteolysis, which enhances RAD18-mediated PCNA monoubiquitination, a key step in TLS and DNA damage tolerance (Gao2016A). This interaction is specific to MAGEA4, as other MAGE proteins like MAGE-A12, MAGE-B10, and MAGE-A1 do not stabilize RAD18 (Gao2016A).

MAGEA4 binds to the RAD6-binding domain (R6BD) of RAD18, displacing RAD6 and inhibiting RAD18's autoubiquitination, which contributes to maintaining RAD18 levels (Griffith-Jones2023Structural). This interaction involves a peptide-binding groove in MAGEA4 that accommodates RAD18, with key residues such as Y361 of RAD18 and M161, I205, and V291 of MAGEA4 being critical for binding (Griffith-Jones2023Structural).

MAGEA4's interaction with RAD18 is characterized by significant chemical shift perturbations, indicating strong binding affinity, and it alters the architecture of the RAD18/RAD6 complex without completely inhibiting RAD18's function in PCNA monoubiquitination (Griffith-Jones2023Structural). This interaction is considered a neomorphic activity specific to cancer cells (Gao2016A).


## References


[1. (Li2021Pathogenicity) Sanyan Li, Xiang Shi, Jingping Li, and Xianrong Zhou. Pathogenicity of the mage family (review). Oncology Letters, October 2021. URL: http://dx.doi.org/10.3892/ol.2021.13105, doi:10.3892/ol.2021.13105. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2021.13105)

[2. (Tsang2020Differential) Yiu Huen Tsang, Yumeng Wang, Kathleen Kong, Caitlin Grzeskowiak, Oksana Zagorodna, Turgut Dogruluk, Hengyu Lu, Nicole Villafane, Venkata Hemanjani Bhavana, Daniela Moreno, Sarah H Elsea, Han Liang, Gordon B Mills, and Kenneth L Scott. Differential expression of magea6 toggles autophagy to promote pancreatic cancer progression. eLife, April 2020. URL: http://dx.doi.org/10.7554/elife.48963, doi:10.7554/elife.48963. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.48963)

[3. (Caballero2010Frequent) Otavia L. Caballero, Qi Zhao, Donata Rimoldi, Brian J. Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F. Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D. Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J. Van den Eynde, Lloyd J. Old, Xin Lu, Jonathan Cebon, Robert L. Strausberg, and Andrew J. Simpson. Frequent mage mutations in human melanoma. PLoS ONE, 5(9):e12773, September 2010. URL: http://dx.doi.org/10.1371/journal.pone.0012773, doi:10.1371/journal.pone.0012773. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0012773)

[4. (Freiberger2022Combinational) Sandra N. Freiberger, David Holzmann, Grégoire B. Morand, Martin Hüllner, Mitchell P. Levesque, Reinhard Dummer, Viktor H. Koelzer, and Niels J. Rupp. Combinational expression of tumor testis antigens ny-eso-1, mage-a3, and mage-a4 predicts response to immunotherapy in mucosal melanoma patients. Journal of Cancer Research and Clinical Oncology, 149(9):5645–5653, December 2022. URL: http://dx.doi.org/10.1007/s00432-022-04514-z, doi:10.1007/s00432-022-04514-z. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00432-022-04514-z)

[5. (Gao2016A) Yanzhe Gao, Elizabeth Mutter-Rottmayer, Alicia M. Greenwalt, Dennis Goldfarb, Feng Yan, Yang Yang, Raquel C. Martinez-Chacin, Kenneth H. Pearce, Satoshi Tateishi, Michael B. Major, and Cyrus Vaziri. A neomorphic cancer cell-specific role of mage-a4 in trans-lesion synthesis. Nature Communications, July 2016. URL: http://dx.doi.org/10.1038/ncomms12105, doi:10.1038/ncomms12105. This article has 58 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms12105)

[6. (FujiwaraKuroda2018Prognostic) Aki Fujiwara-Kuroda, Tatsuya Kato, Takehiro Abiko, Takahiro Tsuchikawa, Noriaki Kyogoku, Masaomi Ichinokawa, Kimitaka Tanaka, Takehiro Noji, Yasuhiro Hida, Kichizo Kaga, Yoshiro Matsui, Hiroaki Ikeda, Shinichi Kageyama, Hiroshi Shiku, and Satoshi Hirano. Prognostic value of magea4 in primary lung cancer depends on subcellular localization and p53 status. International Journal of Oncology, May 2018. URL: http://dx.doi.org/10.3892/ijo.2018.4425, doi:10.3892/ijo.2018.4425. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2018.4425)

7. (Griffith-Jones2023Structural) Structural Insights into The Role of MAGEA4 in RAD18 Regulation: Implications for Ubiquitin Ligase-Binding across the MAGE Protein Family. This article has 0 citations.

[8. (Hagiwara2016Consequences) Yoshio Hagiwara, Lina Sieverling, Farina Hanif, Jensy Anton, Eleanor R. Dickinson, Tam T. T. Bui, Antonina Andreeva, Perdita E. Barran, Ernesto Cota, and Penka V. Nikolova. Consequences of point mutations in melanoma-associated antigen 4 (mage-a4) protein: insights from structural and biophysical studies. Scientific Reports, April 2016. URL: http://dx.doi.org/10.1038/srep25182, doi:10.1038/srep25182. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep25182)

[9. (Verma2024Melanoma) Shiv Verma, Diya Swain, Prem Prakash Kushwaha, Smit Brahmbhatt, Karishma Gupta, Debasish Sundi, and Sanjay Gupta. Melanoma antigen family a (mage a) as promising biomarkers and therapeutic targets in bladder cancer. Cancers, 16(2):246, January 2024. URL: http://dx.doi.org/10.3390/cancers16020246, doi:10.3390/cancers16020246. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16020246)